Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of TNP-2092 in Healthy Chinese Participants
NCT06394518Phase 1Completed
- Sponsor
- TenNor Therapeutics
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rifaquizinone in acute bacterial skin and skin structure infection (ABSSSI) and prosthetic joint infection (PJI) (4 arms), sponsored by TenNor Therapeutics. Primary endpoints: Percentage of Participants With Adverse Events, Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity and 2 more. Started Jul 2022; status: completed.
02
Drugs
rifaquizinone
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT06394518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394518.